This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
This week on the CLL Society website in our 2015 conference coverage section, we feature an interview with me by a fellow CLL patient, Carol Preston of Patient Power where I quickly outline my take on three papers on CLL from the 2015 American Society of Clinical Oncology (ASCO) Annual meeting.
ASCO focuses more on solid tumor cancers, so the news on CLL tends to be scarce, but nevertheless these 3 abstracts highlighted some interesting data, specifically:
- A new prognostic scale
- Data from a Phase I clinical trial on a new non-chemo based triplet therapy
- Data from a Phase III trial studying Bendamustine with and without ibrutinib
In the website posting, I go into more detail, and of course provide a link to the source material itself so we can all form our own opinions.
Your comments are always welcome.
I am off to iwCLL 2015 in a few weeks where I will be speaking on a panel with Drs. Kanti Rai and Michael Keating and others on how to improve patient access to expensive cancer medications. I also plan to meet other CLL patients and interview the experts gathered at the meeting in Sydney, Australia.
We are all in this together.
Brian Koffman, MD